Japan's health minister says the efficacy of Pfizer vaccine was endorsed by a ministry panel, paving the way for a final approval within days.
Health Minister Norihisa Tamura says a formal approval is expected Sunday. The vaccine is already administered in the U.S. and many other countries since December.
Vaccines are considered key to holding the delayed Olympics this summer. Japan is expected to receive 144 million doses from Pfizer, 120 million from AstraZeneca and about 50 million from Moderna before the end of this year, enough to cover its population.
Japan must rely on imports, many subject to the EU's export control, and a cause for concern about supplies. Vaccines developed by Japan are still in the early stages.
About 20,000 front-line medical workers at hospitals in Japan will get their first shots beginning the middle of next week.
About 3 million other medical workers will be next, followed by elderly people getting their shots in April. By June, it's expected all others will be eligible.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)